Orasure Technologies
Open
$3.03
Prev. Close
$3.04
High
$3.05
Low
$3.03
Market Snapshot
$212.33M
-3.1
-0.26
$185.83M
500
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 500 full-time employees. The firm improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
emptyResult
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 500 full-time employees. The firm improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
Recently from Cashu
Altai Urges Strategic Governance Reform at Orasure Technologies for Enhanced Leadership
Orasure Technologies Faces Call for Strategic Governance Reform In a significant development for Orasure Technologies, Altai recently submits a letter to the board urging immediate governance reforms…
OraSure Technologies Reports 25% Revenue Growth Fueled by Diagnostic Innovations
OraSure Technologies Sees Strong Revenue Growth Driven by Diagnostic Innovations OraSure Technologies announces significant achievements in its fourth quarter of 2026, highlighting a 25% year-over-yea…
Please provide the specific text or article content you would like me to summarize into a title.
I apologize, but I need the specific text or article content in order to create a summary. Please provide the text you want summarized, and I will be happy to help!
OraSure Technologies Reports 25% Revenue Growth Driven by Innovations in Oral Fluid Diagnostics
OraSure Technologies: Advancements in Oral Fluid Diagnostics Drive Growth OraSure Technologies announces remarkable growth in its Q4 earnings report for 2026, showcasing a 25% year-over-year increase…